Menu ×

HEALTHCARE & PHARMACEUTICAL

Trastuzumab Biosimilar Market Segmentation by Application Type (Breast Cancer, Colorectal Cancer, Leukemia, and Others); and by Distribution Channel (Online and, Offline) – Global Demand Analysis and Opportunity Outlook 2021-2029

  • Text Size:

Extensive insights into the Growth of Trastuzumab Biosimilar Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More

Trastuzumab Biosimilar Market Highlights 2020-2029

Trastuzumab biosimilar market is estimated to grow with a moderate CAGR during the forecast period, i.e., 2021-2029. Extensive research associated with cancer treatment in western countries, along with the growing investment in the development of advanced therapies are expected to fuel the progress of this market. The growth of the market can also be attributed to factors such as the increasing geriatric population and changing lifestyle. According to the data collected from World Health Organization, in 2020, cancer was the leading cause of death worldwide, accounting for nearly 10 million deaths.

Trastuzumab Biosimilar Market

The market is segmented based on application type into breast cancer, colorectal cancer, leukemia, and others, out of which, the breast cancer segment is anticipated to grab the largest share by the end of 2021 on account of increasing incidence and increasing prevalence of breast cancer globally. Moreover, colorectal cancer segment is also projected to contribute to the growth of the segment during the forecast period due to the rising incidence in colon and rectal cancer worldwide. According to World Health Organization, the most common in 2020 (in terms of new cases of cancer) were breast cancer (2.26 million cases), followed by colon and rectum cancer (1.93 million cases) on the third number.

On the basis of distribution channel, the offline segment in the global trastumuzab biosimilar market is projected to grow with a significant CAGR over the forecast period. The growth of the segment can be attributed to the presence of retail and hospital pharmacies and an expanded customer base. Although, online segment is also expected to contribute to the market due to increasing dependence on e-commerce platforms and rising internet penetration.

Trastumuzab Biosimilar Market Regional Synopsis

Geographically, the market is segmented into North America, Latin America, Europe, Asia Pacific and the Middle East & Africa region. The market in the Europe is predicted to grow at the highest CAGR over the forecast period owing to factors such as increasing prevalence of breast cancer, strong clinical pipeline, increasing research and drug development activities propels market growth in the region. Furthermore, in 2021, the market in Asia Pacific is evaluated to occupy the largest share in terms of revenue, Asia Pacific is a promising revenue contributor which is expected to grow at rapid pace in upcoming year. Countries such as Japan, India and China are major contributors to the growth of this market. Emerging and huge population base countries such as China and India offer tremendous market opportunities due to investments for trastumuzab biosimilar research. As per the analysis of World Health Organization, cancer accounts for 20% of deaths in the European Region.

Trastumuzab Biosimilar Market

The global trastumuzab biosimilar market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Market Segmentation

Our in-depth analysis of the global trastumuzab biosimilar market includes the following segments:

By Application Type

  • Breast Cancer
  • Colorectal Cancer
  • Leukemia
  • Others

By Distribution Channel

  • Online
  • Offline

Growth Drivers

  • Rising Prevalence of Cancer
  • Increasing Geriatric Population in the World

Challenges

  • Side-Effects Associated with the Use

Top Featured Companies Dominating the Market

  • Amgen Inc.
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • Aryogen Biopharma
  • Biocon Limited
  • Celltrion Inc.
  • Pfizer Inc.
  • Merck & Co. Inc.
  • Accord Healthcare Ltd.
  • Gedeon Richter PLC
  • Genor Biopharma Company Ltd.
  • Mabion S.A.
  • Mylan N.V.
  • Roche Holding AG

FREQUENTLY ASKED QUESTIONS


Related Reports


Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved